[HTML][HTML] Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy

E Felip, C Gridelli, P Baas, R Rosell, R Stahel… - Annals of …, 2011 - Elsevier
Abstract The 1st ESMO Consensus Conference on lung cancer was held in Lugano,
Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of …

[HTML][HTML] 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer

R Stahel, N Thatcher, M Früh, C Le Péchoux… - Annals of …, 2011 - Elsevier
Abstract The 1st ESMO Consensus Conference on lung cancer was held in Lugano,
Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of …

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

G D'addario, M Früh, M Reck, P Baumann… - Annals of …, 2010 - annalsofoncology.org
Non-small-cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancer cases.
Approximately 90% of lung cancers among men and 80% among women are related to …

Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line

A Al-Farsi, PM Ellis - Frontiers in Oncology, 2014 - frontiersin.org
Historically, the treatment algorithm applied to non-small cell lung cancer (NSCLC) was the
same for all histologic subtypes. However, recent advances in our understanding of the …

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D Planchard, ST Popat, K Kerr, S Novello… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: are patients undertreated?

AG Sacher, LW Le, A Lau, CC Earle, NB Leighl - Cancer, 2015 - Wiley Online Library
BACKGROUND New therapies for metastatic non–small cell lung cancer (NSCLC) have
improved survival in clinical trials. However, only a minority of patients receive systemic …

Non–small cell lung cancer

DS Ettinger, W Akerley, H Borghaei, AC Chang… - Journal of the National …, 2012 - jnccn.org
Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S Peters, AA Adjei, C Gridelli, M Reck… - Annals of …, 2012 - annalsofoncology.org
Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and
the leading cause of human cancer deaths worldwide [1]. While it has been the most …

Therapeutic strategy for treatment of metastatic non-small cell lung cancer

M Berhoune, E Banu, F Scotte… - Annals of …, 2008 - journals.sagepub.com
Objective: To review the current practices for metastatic non–small cell lung cancer (NSCLC)
management and highlight the latest progress. Data Sources: A literature review using …